Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist (2016) 1.51

Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. Oncologist (2015) 1.15

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med (2016) 0.80

Metabolic Signatures of Human Breast Cancer. Mol Cell Oncol (2015) 0.79

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. PLoS One (2015) 0.78

Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma. Int J Clin Exp Pathol (2015) 0.77

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn (2015) 0.76

[Metabolome analysis of solid tumors]. Pathologe (2016) 0.75

The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02

An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20

IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol (2011) 5.73

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 5.62

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer (2009) 4.45

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst (2010) 3.00

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 2.40

IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood (2012) 2.23

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood (2010) 2.15

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med (2012) 2.12

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia (2010) 1.72

An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol (2011) 1.70

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood (2010) 1.41

Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol (2008) 1.34

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood (2012) 1.33

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica (2010) 1.32

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer (2011) 1.31

Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun (2010) 1.31

Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol (2011) 1.26

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest (2013) 1.24

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood (2010) 1.22

Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab (2009) 1.15

Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathol (2012) 1.02

IDH1 and IDH2: not your typical oncogenes. Cancer Cell (2010) 1.00